Researchers developed lactoferrin-modified lipid nanoparticles (LNPs) to deliver NMN across the blood-brain barrier, achieving 62% BBB permeability—significantly higher than unmodified NMN. The formulation showed enhanced pharmacokinetics and selective brain tissue accumulation in rat models without cytotoxicity. This advancement addresses NMN’s poor BBB penetration, a key limitation for neurotherapeutic applications in neurodegenerative disease treatment.
For your business
Lactoferrin-modified NMN nanoparticles achieved 62% BBB permeability in rats, suggesting future oral or IV formulations may improve CNS bioavailability.